Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model
about
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model systemPharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.Model system to define pharmacokinetic requirements for antimalarial drug efficacy.Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variantsAn open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.Assessing Uncertainty in A2 Respiratory Syncytial Virus Viral Dynamics.Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.Zika virus (ZIKV) Replication is Substantially Inhibited by Novel Favipiravir and Interferon-alpha Combination Regimens.Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)Investigating Different Mechanisms of Action in Combination Therapy for Influenza
P2860
Q30398935-3C998CAD-98DA-4E17-8543-6C6CBB0440CEQ30625335-8F886153-E02C-4BC8-9C60-0AE6BA248038Q35007051-9C89BD17-4382-4E4B-92DF-B1907845A139Q35076812-8762C9B4-68EF-481A-8EE7-457BCD1C937CQ35191600-FDC38465-6A2A-4646-8EC2-5215328921C5Q38887711-131EC60D-873B-4F00-8DAA-B1DF70920603Q38955037-97CC8F57-5ED7-4480-8A1C-165EF1D6C094Q39430698-34585B1F-2C0B-43EB-9131-4BF1364105A9Q43046770-B277AC1D-3A91-4563-8C77-83AB62E4ACC6Q47593385-8CD2DA20-D653-4025-A744-8506E04B4A3AQ56479686-E5A54785-E6CD-4E4B-BA70-C8F21EA3AE3FQ58573517-12CEB79F-7F8F-4ABE-AE59-C39630AACA79
P2860
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effect of half-life on the pha ...... neated by a mathematical model
@ast
Effect of half-life on the pha ...... neated by a mathematical model
@en
Effect of half-life on the pha ...... neated by a mathematical model
@nl
type
label
Effect of half-life on the pha ...... neated by a mathematical model
@ast
Effect of half-life on the pha ...... neated by a mathematical model
@en
Effect of half-life on the pha ...... neated by a mathematical model
@nl
prefLabel
Effect of half-life on the pha ...... neated by a mathematical model
@ast
Effect of half-life on the pha ...... neated by a mathematical model
@en
Effect of half-life on the pha ...... neated by a mathematical model
@nl
P2093
P2860
P356
P1476
Effect of half-life on the pha ...... neated by a mathematical model
@en
P2093
Ashley N Brown
George L Drusano
James J McSharry
Jonathan R Adams
Qingmei Weng
Robert Kulawy
P2860
P304
P356
10.1128/AAC.01629-10
P407
P577
2011-01-24T00:00:00Z